Fig. 3From: Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in ChinaCost-effectiveness acceptance curve. Cost-effectiveness acceptability curve results based on 1000 Monte Carlo simulations of the model. The curve presents the probability that the rivaroxaban regimen is cost-effective as a function of willingness-to-pay thresholdBack to article page